Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma

Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma

Purpose: Emerging evidence shows that immune checkpoint inhibitors lead to durable responses in a variety of cancers, including nasopharyngeal carcinoma (NPC), however, combination approaches (i.e., stereotactic body radiation therapy, SBRT) are required to extend this benefit beyond a subset of pat...

Full description

Bibliographic Details
Main Authors: Chen, C. (Author), Chen, G. (Author), Chen, M. (Author), Chen, Y. (Author), Guo, Q. (Author), Guo, Z. (Author), Lin, J. (Author), Lin, S. (Author), Lu, J. (Author), Lu, T. (Author), Pan, J. (Author), Tang, L. (Author), Zong, J. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Immunotherapy
Nasopharyngeal carcinoma
PD-1
Stereotactic body radiotherapy
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items